|NIH Director Welcomes Five New Members to the Advisory Committee
to the Director
Bethesda, Maryland — The National Institutes of Health
(NIH) has selected five individuals to serve as members of the Advisory Committee
to the Director (ACD). Since 1966, the ACD has advised the NIH Director on policy
and planning issues.
“We are delighted to welcome these five outstanding individuals as new members
to the NIH Advisory Committee to the Director,” said NIH Director Elias A. Zerhouni,
M.D. “The success of NIH depends on the willingness of over 21,000 scientists
and public members who come to NIH every year to participate on advisory councils
and peer-review committees. They are a tremendous asset to NIH.”
The new members, who join 11 current members of the council, are Nancy E. Adler,
Ph.D., of San Francisco, California; David Botstein, Ph.D., of Princeton, New
Jersey; Alexander R. Lerner of Glencoe, Illinois; Christine E. Seidman, M.D.,
of Milton, Massachusetts; and Tadataka Yamada, M.D., of King of Prussia, Pennsylvania.
Nancy E. Adler, Ph.D., is Professor of Psychology, Departments
of Psychiatry and Pediatrics at the University of California, San Francisco,
where she is also Vice-Chair of the Department of Psychiatry, and Director of
the Center for Health and Community. She did her undergraduate work at Wellesley
College and received her Ph.D. in Psychology from Harvard University. She has
been elected to membership in the Institute of Medicine of the National Academy
of Sciences, and was named a National Associate of the National Academies. Dr.
Adler’s current work examines the pathways from socioeconomic status (SES) to
health. As director of the MacArthur Foundation Research Network on SES and Health,
she coordinates research spanning social, psychological, and biological mechanisms
by which SES influences health.
David Botstein, Ph.D., is Director and Anthony B. Evnin Professor
of Genomics at the Lewis-Sigler Institute for Integrative Genomics at Princeton
University. Dr. Botstein’s research has centered on genetics, especially the
use of genetic methods to understand biological functions. In the early 1970’s,
he devised novel methods to study budding yeast (Saccharomyces cerevisiae) and
devised novel genetic methods to study the functions of the actin and tubulin
cytoskeletons. In 1980, he began his theoretical contributions on linkage mapping
of the human genome. Linkage mapping of human disease genes became one of the
foundations of the new science of genomics. At Princeton, Dr. Botstein leads
a team of faculty who are teaching a new, experimental introductory science curriculum,
where the basic ideas of physics, chemistry, computer science and biology, along
with the relevant mathematics, are taught together. His current research effort
is devoted to the study of yeast biology at the system level.
Alexander R. Lerner is Chief Executive Officer of the Illinois
State Medical Society, a professional organization representing 14,000 Illinois
physicians. He also holds the position of Chief Executive Officer of ISMIE Mutual
Insurance Company, the state’s largest physician-owned medical malpractice insurer,
as well as of Illinois State Medical Insurance Services, Inc., the management
arm of ISMIE Mutual. He joined the State Medical Society as its CEO in 1981,
after serving as President of his own consulting firm, Governmental Affairs,
Christine E. Seidman, M.D., is a Professor in the Departments
of Medicine and Genetics at Harvard Medical School and Brigham and Women’s Hospital.
She is also an Investigator of the Howard Hughes Medical Institute. She was an
undergraduate at Harvard College and received an M.D. from George Washington
University School of Medicine in 1978. Dr. Seidman served as an intern and resident
in Internal Medicine at Johns Hopkins Hospital and received subspecialty training
in cardiology at the Massachusetts General Hospital. She joined the staff at
Brigham and Women’s Hospital in 1987 and is the Director of the Cardiovascular
Tadataka Yamada, M.D., is Chairman of Research and Development
at GlaxoSmithKline (GSK) and a member of GSK’s Board of Directors. He joined
SmithKline Beecham as a non-executive Member of the Board of Directors in February
1994, and became President of Healthcare Services and Executive Director in February
1996. He was named Chairman of Research and Development, SmithKline Beecham Pharmaceuticals,
in February 1999, and in January 2001, he assumed his current role. He was formerly
Chairman of the Department of Internal Medicine at the University of Michigan
Medical School and Physician-in-Chief of the University of Michigan Medical Center.
Dr. Yamada is a graduate of Stanford University with a B.A. in history. He earned
his M.D. at New York University School of Medicine. He is a gastroenterologist
who has focused his research on the molecular biology of gastrointestinal hormones
and is the editor of the Textbook of Gastroenterology.
The ACD advises the NIH Director on policy matters important to the NIH mission
of conducting and supporting biomedical and behavioral research, research training,
and translating research results for the public. Additional information is available
The Office of the Director, the central office at NIH, is responsible for
setting policy for NIH, which includes 27 Institutes and Centers. This involves
planning, managing, and coordinating the programs and activities of all NIH
components. The Office of the Director also includes program offices which
are responsible for stimulating specific areas of research throughout NIH.
Additional information is available at http://www.nih.gov/icd/od/.
The National Institutes of Health (NIH) — The Nation's Medical Research
Agency — is a component of the U. S. Department of Health and Human
Services. It is the primary Federal agency for conducting and supporting basic,
clinical, and translational medical research, and it investigates the causes,
treatments, and cures for both common and rare diseases. For more information
about NIH and its programs, visit http://www.nih.gov.